Clinical Drug Experience Knowledgebase

alemtuzumab (campath) (1 trial)

allogeneic hematopoietic stem cells (Hemacord) (1 trial)

anagrelide (agrylin) (1 trial)

autologous hematopoietic cell (1 trial)

bleomycin (blenoxane) (2 trials)

carmustine (bicnu) (1 trial)

chlorambucil (Leukeran) (2 trials)

cisplatin (platinol) (2 trials)

cyclophosphamide (cytoxan) (10 trials)

cytarabine (cytosar-u) (10 trials)

dacarbazine (dtic-dome) (2 trials)

daunorubicin (cerubidine) (3 trials)

doxorubicin (Doxil) (9 trials)

etoposide (vepesid) (2 trials)

fludarabine (fludara) (8 trials)

gemcitabine (gemzar) (1 trial)

gemtuzumab ozogamicin (mylotarg) (1 trial)

idarubicin (idamycin) (3 trials)

ifosfamide (ifex) (3 trials)

interferon alpha-2a (roferon-a) (1 trial)

interferon alpha-2b (Intron-A) (2 trials)

lomustine (2 trials)

melphalan (alkeran) (2 trials)

mercaptopurine (purinethol) (1 trial)

methylprednisolone (medrol) (2 trials)

mitoguazone (1 trial)

naltrexone (revia) (2 trials)

pegylated-interferon (1 trial)

prednisone (meticorten) (7 trials)

pronabol (1 trial)

rituximab (rituxan) (16 trials)

ruxolitinib (jakafi) (3 trials)

urea (5 trials)

vinblastine (velban) (2 trials)

vincristine (oncovin) (8 trials)

vinorelbine (navelbine) (2 trials)

90y-dota-epratuzumab (1 trial)

acalabrutinib (calquence) (1 trial)

autologous mononuclear stem cell (1 trial)

azacitidine (vidaza) (1 trial)

bendamustine (treanda) (4 trials)

blinatumomab (blincyto) (1 trial)

bortezomib (velcade) (2 trials)

daratumumab (darzalex) (1 trial)

dexamethasone (1 trial)

eltrombopag (promacta) (1 trial)

epirubicin (ellence) (1 trial)

fish oil (Omegavan) (1 trial)

ibrutinib (imbruvica) (3 trials)

idelalisib (zydelig) (1 trial)

lenalidomide (revlimid) (1 trial)

mitoxantrone (novantrone) (2 trials)

obinutuzumab (gazyva) (2 trials)

ofatumumab (arzerra) (1 trial)

procarbazine (matulane) (1 trial)

sargramostim (leukine) (3 trials)

sirolimus (rapamune) (1 trial)

temozolomide (temodar) (1 trial)

temsirolimus (torisel) (1 trial)

venetoclax (venclexta) (3 trials)

vindesine (1 trial)

everolimus (zortress) (1 trial)